C-7DLXAlnylam
RNAi therapeutics, gene silencing, siRNA delivery
modulatingrna therapeutic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-7DLX
C-7DLXC-7DLXRNAi therapeutics, gene silencing, siRNA delivery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
This is a first in human, randomized, double-blind (DB), placebo-controlled, single ascending dose (SAD), Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of ALN-6222 administered subcutaneously (SC) in adult participants with obesity.
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
On Wednesday, April 15, over 600 IINE community members gathered at the Omni Seaport Hotel in Boston for the 44th Golden Door Award Gala to honor Dr. Yvonne Greenstreet, the Chief Executive Officer of Alnylam Pharmaceuticals. We celebrate Dr. Greenstreet’s decades-long commitment to delivering transformative medicines to patients across the globe and her dedication to uplifting diverse voices and perspectives. During her speech, Dr. Greenstreet reminded us the U.S. was built "not on privilege, but on potential" where everyone, including herself, can dream and grow to become American success stories. We are proud to honor her as a leader born outside of the United States, who has made outstanding contributions to American society. We are so thankful to all attendees, to our Suitcase Stories® performer Efdjeen who courageously shared her journey; and to Back Bay Chorale’s ESOL Chorus for bringing us all together in song. Thank you to our generous sponsors and to our community who
On Wednesday, April 15, IINE honored Dr. Yvonne Greenstreet, Alnylam Pharmaceuticals CEO, at the 44th Golden Door Award Gala. Growing up in a large diverse household inspired Dr. Yvonne Greenstreet to have a greater impact on patients with various backgrounds. As Alnylam Pharmaceuticals CEO, Dr. Greenstreet has delivered transformative medicines to patients across the globe. She exemplifies the drive, ingenuity, and compassion of refugees and immigrants celebrated through the Golden Door Award, which honors their tremendous contributions to society.
This video is intended for Investors and Media. Alnylam CEO Yvonne Greenstreet reflects on Alnylam's performance in 2025 and the year ahead. Read her full reflection and download Alnylam's 2025 annual report here: https://go-alnylam.com/3OnWBgI ALN_CORP_AR2025_YG
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.
The purpose of this study is to: * evaluate the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 in patients with obesity * evaluate the safety, tolerability, efficacy, PK, and PD of multiple doses of ALN-2232 co-initiated with tirzepatide in patients with obesity
“I’ve seen how diversity of all types—backgrounds, cultures, perspectives—really does spark creativity really does spark creativity,” Dr. Yvonne Greenstreet, the Chief Executive Officer of Alnylam Pharmaceuticals, shared with audience members while receiving the 2024 Healthcare Businesswomen’s Association Woman of the Year award. Growing up in a diverse household with an English father and a Ghanaian mother, Greenstreet witnessed first-hand how diverse voices and perspectives help create the best solutions. We are excited to honor Dr. Yvonne Greenstreet as the recipient of IINE’s 44th annual Golden Door Award for her decades-long commitment to delivering transformative medicines to patients across the globe. The prestigious honor is given each year to a leader born outside of the United States, who has made outstanding contributions to American society, as Dr. Greenstreet has. Join us in honoring Dr. Greenstreet on April 15, 2026, at the Omni Seaport Hotel in Boston. and the contributi
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285
The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed * Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
#ALNY Alnylam Pharmaceuticals 2025 Q3 Earnings: Alnylam Pharmaceuticals reported a significant revenue increase and exceeded EPS expectations in Q3 2025, driven by strong product demand and strategic pipeline advancements. - Revenue: $1.25 billion - Adj. EPS: $2.90 vs. forecast $0.46 (10 analysts) - Net Product Revenue Growth: 103% - Guidance Raised: $2.95B to $3.05B for 2025 "Alnylam’s impressive third quarter financial results underscore our ability to consistently deliver innovative medicines to patients around the world," said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. If you enjoyed this video, please like, subscribe, and hit the notification bell to stay updated with our latest stock analysis and market insights. Leave a comment below with your thoughts on the video, and any other stocks you'd like us to cover. *Check out our latest videos on more earnings:* - #ILMN Illumina 2025 Q3 Earnings: https://www.youtube.com/watch?v=6MRAmwIYA_c - #WY Weyerhaeus
The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.
The purpose of this study is to: * Evaluate the efficacy of nucresiran compared to placebo on reducing all-cause mortality and cardiovascular (CV) events * Evaluate the efficacy of nucresiran compared to placebo on additional assessments of CV events and/or death * Evaluate the efficacy of nucresiran compared to placebo on patient-reported health status and health-related quality of life
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
Alnylam Pharmaceuticals has pioneered RNA interference therapeutics, or RNAi. This groundbreaking technology has increased the company’s success rates of bringing medicines through the clinical pipeline—leading to the approval and launch of six new medicines in just six years. Their CEO Dr. Yvonne Greenstreet spoke with Jerry Lee, head of biopharma banking in the global healthcare group, about the applications of Alnylam’s Nobel Prize-winning RNAi technology, her vision for the future of biotech, and the importance of a patient-focused and teamwork-oriented culture. Dr. Greenstreet also discussed her career journey and leadership philosophy—as one of the only women of color leading a major pharmaceutical company. This session was recorded on April 23, 2025. Chapters 0:00 Introduction 1:45 Alnylam foundation 4:10 Innovation milestones 7:48 5-year goals 9:32 Managing risk 12:26 Golden era of biotech 13:38 Utilizing AI 15:50 Career journey 17:58 Alnylam culture 22:31 Future of the indu
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
#ALNY Alnylam Pharmaceuticals 2024 Q4 & Full Year Earnings: Alnylam Pharmaceuticals reported strong revenue growth and exceeded EPS expectations in Q4 2024, driven by robust product demand and strategic advancements. - Total Revenue Q4: $593.2M - Net Product Revenue Growth: 30% Q4, 33% FY - Net Loss Q4: $83.8M - Adj. EPS: $0.06 vs. forecast -$0.68 (12 analysts) - 2025 Revenue Guidance: $2.05B - $2.25B - Cash Reserves: $2.69B "2024 was another year of impressive execution for Alnylam, generating product revenues of over $1.6 billion, reflecting growth of 33% compared to 2023, and highlighting the strength of our base business in hATTR-PN and Rare in both the U.S. and international markets." - Yvonne Greenstreet, CEO If you enjoyed this video, please like, subscribe, and hit the notification bell to stay updated with our latest stock analysis and market insights. Leave a comment below with your thoughts on the video, and any other stocks you'd like us to cover. *Check out our la
Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, joined Flagship Pioneering Founder and CEO Noubar Afeyan in our Flagship Studio for a FutureCast conversation on what’s unique about leading a platform company, balancing breadth versus depth when it comes to pipeline development, and how a commitment to the science and a shared vision fuels innovation. About Flagship Pioneering: Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, Moderna , Omega Therapeutics, Sana Biotechnology, Seres Therapeutics, and Tessera Therapeutics. Website: www.flagshipioneering.com Linkedin: www.linkedin.com/company/flagship
Alnylam Pharmaceuticals CEO Yvonne Greenstreet discusses why RNAI can be used to treat an array of diseases, the company's medicines using this technology, and more. SUBSCRIBE ➡️ https://bit.ly/3Fu15JK Visit our website: https://www.barrons.com/ Follow us on Instagram ➡️ https://www.instagram.com/barrons Like us on Facebook ➡️ https://www.facebook.com/barrons Follow us on Twitter ➡️ https://twitter.com/barronsonline Barron's is the world's premier investing publication since 1921. #Barrons #podcast
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.
The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.
By late June or early July we’ll know whether Alnylam’s decision to alter the design of its phase 3 ‘Healios B’ study of Amvuttra (vutrisiran) in transthyretin amyloidosis with cardiomyopathy (ATTR-CM) was a good one. The short-interfering RNA (siRNA) drug is already approved in ATTR with polyneuropathy (ATTR-PN), a debilitating, fatal condition in which misfolded transthyretin proteins clump together and create damaging deposits in the peripheral nerves. But about ten times as many patients develop ATTR-CM, in which protein deposition occurs in cardiac tissue and gives rise to a form of heart failure. Alnylam is, therefore, attempting to establish Amvuttra in this category as well. An earlier drug from the same stable, Onpattro (patisiran), failed to deliver in ATTR-CM, but the company argues that it needed a longer, larger trial to detect the survival signals it is now seeking with Amvuttra in the Healios B study. Pfizer is the current category leader in this space with its V
This is a single-center observational study evaluating the potential value of NfL as a biomarker for diagnosis, detection of disease onset, monitoring of disease progression, and treatment response in asymptomatic carriers of TTR variants and symptomatic hATTR amyloidosis patients with polyneuropathy.
By late June or early July we’ll know whether Alnylam’s decision to alter the design of its phase 3 ‘Healios B’ study of Amvuttra (vutrisiran) in transthyretin amyloidosis with cardiomyopathy (ATTR-CM) was a good one. The short-interfering RNA (siRNA) drug is already approved in ATTR with polyneuropathy (ATTR-PN), a debilitating, fatal condition in which misfolded transthyretin proteins clump together and create damaging deposits in the peripheral nerves. But about ten times as many patients develop ATTR-CM, in which protein deposition occurs in cardiac tissue and gives rise to a form of heart failure. Alnylam is, therefore, attempting to establish Amvuttra in this category as well. An earlier drug from the same stable, Onpattro (patisiran), failed to deliver in ATTR-CM, but the company argues that it needed a longer, larger trial to detect the survival signals it is now seeking with Amvuttra in the Healios B study. Pfizer is the current category leader in this space with its V
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and PD of multiple doses of KHK.
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Before she accepted a recent offer to become chief executive of Alnylam Pharmaceuticals, one of Massachusetts’ biggest biotechs, Yvonne Greenstreet consulted two women she respects, her mother and her daughter.Miranda Greenstreet, 88, is from the West African nation of Ghana and often blazed trails, her daughter said. She married a white Englishman whom she met in the 1950s when they were students at the London School of Economics. Later, she set up an institute that promoted adult literacy in Ghana. When Yvonne Greenstreet called to ask if she should take the job, she recalled, her mother didn’t hesitate, saying, “Is there a choice?”AdvertisementGreenstreet’s daughter, a medical student at the University of California, San Francisco, had a similar reaction.“Mom, if you think you can, please do it,” she recounted Emma Greenstreet saying, “because you have no idea what it’s going to mean to young women like myself to see you in the position.”Greenstreet, Alnylam’s chief operating office
The purpose of this study is to evaluate the effect of ALN-AGT01 on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of ALN-AGT01.
This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.
The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
The purpose of this study is to collect and evaluate pregnancy outcomes, pregnancy complications, and fetal/neonatal/infant outcomes in women exposed to patisiran-LNP.
To evaluate the effectiveness of patisiran in patients with ATTRv amyloidosis with polyneuropathy who have a V122I or T60A mutation.
The purpose of this study is to evaluate the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of subcutaneous (SC) ALN-AGT01 (zilebesiran) in participants with hypertension. The study will be conducted in 4 parts: Part A will be a single ascending dose (SAD) phase in hypertensive participants, Part B will be a single dose (SD) phase in hypertensive participants with controlled salt intake, Part D will be a MD phase in hypertensive participants who are obese, and Part E will be an open-label SD phase with co-administration of irbesartan in hypertensive patients.
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of patisiran in participants with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with disease progression after liver transplant.
The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in participants with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran subcutaneous (SC) injection once every 3 months (q3M) or the reference comparator patisiran intravenous (IV) injection once every 3 weeks (q3w) during the 18 month Treatment Period. This study will use the placebo arm of the APOLLO study (NCT01960348) as an external comparator for the primary and most other efficacy endpoints during the 18 Month Treatment Period. Following the 18 Month Treatment Period, all participants will be randomized to receive vutrisiran 50 mg SC injection once every 6 months (q6M) or vutrisiran 25 mg q3M in the Randomized Treatment Extension (RTE) Period. Upon implementation of Amendment 6, participants receiving vutrisiran SC 50 mg q6M will transition to vutrisiran SC 25 mg q3M at their next scheduled dosing.
The purpose of this study is to evaluate the safety and tolerability of single or multiple doses of ALN-AAT02. The study will be conducted in 2 sequential phases in which Part A will be a single-ascending dose (SAD) phase in healthy participants, and Part B will be a multiple-ascending dose (MAD) phase in participants with ZZ type alpha-1 antitrypsin deficiency (PiZZ) and biopsy-proven alpha-1 antitrypsin (AAT) deficiency-associated liver disease.
"Curative" is not a word that we can use very often in medicine, especially when talking about diseases such as cancer and rare genetic disorders. However, the first curative therapies are already here, and the wave is coming. The Food and Drug Administration approved three gene- and cell-based therapies last year. In contrast to traditional therapeutics that alleviate symptoms alone, gene- and cell-based therapies hold the promise of treating the underlying cause of a disorder for long periods of time, perhaps even curing or preventing disease. Excitement around recent approvals of the first gene therapies comes with a desire to speed development of similar therapeutics in the pipeline, as well as concern over upfront costs that could run hundreds of thousands of dollars for each patient. How do we ensure that patients get access for durable therapies while companies are rewarded for their investment? Some are turning to financial innovation, hoping to reallocate payment timing, risk,
The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).
The purpose of this study is to determine the long-term safety, tolerability and pharmacokinetics of givosiran (ALN-AS1) in AIP patients who completed study ALN-AS1-001 (NCT02452372).
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALN-HBV in healthy adult volunteers and patients with chronic hepatitis B virus (HBV) infection. In addition, the study will assess antiviral efficacy of ALN-HBV in patients with HBV.
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-TTRSC02 in healthy subjects.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of lumasiran in healthy adult volunteers and subjects with primary hyperoxaluria type 1 (PH1). In Part A, single ascending dose (SAD) part, healthy adults were dosed with lumasiran or placebo once. In Part B, multiple ascending doses (MAD) part, patients with primary hyperoxaluria type 1 (PH1) were dosed with lumasiran or placebo. All patients that initially received placebo received lumasiran after completing placebo dosing.
The purpose of this study was to evaluate the safety and effectiveness of revusiran (ALN-TTRSC) in adults with transthyretin-mediated amyloidosis (ATTR), whose disease has continued to worsen after liver transplantation. Dosing has been discontinued; patients are being followed-up for safety.
Dr Kevin Fitzgerald, Alnylam Pharmaceuticals, discusses this new therapeutic strategy targteting PCSK9, and the results and implications of the Phase I study with ALN-PCSsc"
The purpose of this study is to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered ALN-AAT in Healthy Adult Subjects and Patients with ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease.
The purpose of this study was to evaluate the safety and efficacy of revusiran (ALN-TTRSC) in patients with transthyretin (TTR) mediated Familial Amyloidotic Cardiomyopathy. Dosing has been discontinued; patients are being followed-up for safety.
The purpose of this study was to evaluate the safety and clinical activity of long-term dosing with revusiran (ALN-TTRSC). Dosing has been discontinued; patients are being followed-up for safety.
The purpose of this study is to determine the pharmacokinetics, pharmacodynamics and exploratory clinical activity of ALN-TTRSC (revusiran) in Patients with Transthyretin (TTR) Cardiac Amyloidosis.
The purpose of this study is to evaluate the safety and efficacy of patisiran (ALN-TTR02) in patients with transthyretin (TTR) mediated amyloidosis. An open-label, single-arm, long-term follow-up extension study NCT02510261 (ALN-TTR02-006) was initiated to provide participants who completed this study with continued patisiran-LNP (lipid nanoparticle) treatment.
The purpose of this study is to evaluate the safety and tolerability of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ALN-TTRSC (revusiran) in healthy volunteer subjects.
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-TTR02 in healthy volunteer subjects.
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-PCS02 in subjects with Elevated LDL-Cholesterol (LDL-C).
This study provides a mechanism for continued administration of ALN-VSP02 therapy to patients with cancer who completed participation in another ALN-VSP02 clinical study. The primary objective of this study is to collect long term safety data.
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of ALN-TTR01 in patients with transthyretin (TTR) mediated amyloidosis (ATTR).
To evaluate the efficacy and safety of ALN-RSV01 plus standard of care in RSV infected lung transplant patients
The purpose of the study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ALN-VSP02, an RNAi therapeutic, in patients with advanced solid tumors with liver involvement.
To evaluate the safety,tolerability and antiviral activitity of ALN-RSV01 in RSV infected lung transplant patients
The purpose of this study is to determine the safety, tolerability and efficacy of intranasal ALN-RSV01 versus placebo, administered once daily for 5 days to a healthy male volunteers experimentally inoculated with RSV
Dr Yvonne Greenstreet's 30-Year Leadership Journey to Alnylam CEO | April Little posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sig … -traditional pharmacy career paths and working in clinical trials to pursuing a fellowship in Global Regulatory Affairs. She reflects on how experiences in clinical research, healthcare consulting, and managed care helped shape her career interests and provided valuable skills that continue to influence her work today. Jenny also discusses the importance of diversity, equity, and inclusion in the pharmaceutical industry, highlighting the need for equitable representation in c … and technology are advancing faster than the frameworks designed to assess and fund them. Budgets aren't growing at the same pace as innovation, and for some breakthrough therapies, the current assessment processes simply aren't fit for purpose. 🔹 Launching a medicine is not just about approval. TGA registration is only one piece. Reimbursement, clinician education, real-world evidence, and patient access strategy all need to align. Missteps at any stage can delay or preven
EX-99.2 4 d240930dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Contacts: Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Announces Planned CEO Leadership Transition - Founding Alnylam CEO John Maraganore to Transition CEO Leadership to Alnylam President Yvonne Greenstreet at Year End – CAMBRIDGE, Mass., – October 28, 2021 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the planned CEO transition of John M … through that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by silencing messenger RNA (mRN … ic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the potential treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO ® &n
Alnylam Names Dr. Yvonne Greenstreet New CEO | Alnylam® Newsroom Skip to main content Investors For Investors Stock Information Investors Toolkit Events & Presentations Financial Information SEC Filings Corporate Governance Analyst Coverage Financial Statements Ownership Profile Annual Meetings Press Releases Capella (Scientific Presentations) FAQs Medical Professionals For Medical Professionals Genetic Testing & Counseling Early Access Program Medical Publication Support Investigator Initiated Studies (IIS) Patients For Patients Amyloidosis Acute Hepatic Porphyria Primary Hyperoxaluria Patien … Innovative Companies for 2026 Leadership Alnylam Awarded 2026 Scientific Impact Award by MassBio Leadership Alnylam BioVenture Challenge: Supporting the Next Generation of Biotech Leaders Share this: Categories Leadership Perspectives RNAi Patient Focus Responsibility Careers & Culture Content Types Articles Podcasts Presentations Videos See All News › Related Content See All News › Leadership Alnylam Named One of Fast Company's Most Innovative Companies for 2026 Lea … Innovative Companies for 2026 Leadership Alnylam Awarded 2026 Scientific Impact Award by MassBio Leadership Alnylam BioVenture Challenge: Supporting the Next Generation of Biotech Leaders See All News › --> See All News › FOLLOW US Visit our social channels to learn more about the innovative work we are doing at Alnylam. Our Company Our Science Our Products Our News Investors Medical Professionals Patients Job Seekers Clinical Trials Corporate Responsibility Diversity, Equity
Boston Magazine - Yvonne Greenstreet is getting decorated... Facebook Log In Boston Magazine's Post Boston Magazine Verified account May 20 · Shared with Public Yvonne Greenstreet is getting decorated on both sides of the Atlantic—and earning every honor. The London-born CEO of Alnylam was awarded the Order of the British Empire last year and the Golden Door Award from the International Institute of New England this year. Meanwhile, her Cambridge pharma company just launched a $250 million expansion of its Norton manufacturing facility and endowed a fund for emerging scientists at MIT. Di
Alnylam - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigatio | Alnylam Skip to main content Investors For Investors Stock Information Investors Toolkit Events & Presentations Financial Information SEC Filings Corporate Governance Analyst Coverage Financial Statements Ownership Profile Annual Meetings Press Releases Capella (Scientific Presentations) FAQs Medical Professionals For Medical Professionals Genetic Testing & Counseling Early Access Program Medical Publication Support Investigator Initiated Studies (IIS) Patients For Patients Amyloido … breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) … ople afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO ® (patisiran), AMVUTTRA ® (vutrisiran), GIVLAARI ® (givosiran
Jim Marshall - Alnylam Pharmaceuticals, USA | Security of Supply Chain Speaker You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. October 17th & 18th, 2022 Digital Conference 8:00AM EST // 1:00PM BST // 2:00PM CEST Home home What's On? Agenda Our Speake
Making our Medicines | Alnylam Skip to main content Our Company About Alnylam Leadership Diversity, Equity & Inclusion Patient Access Philosophy Corporate Responsibility Alnylam Challengers Transparency Grants & Giving Investigator Initiated Studies (IIS) Our Science The Science of RNAi Delivery Platforms Making Our Medicines Therapeutic Areas Pipeline Clinical Trials Scientific Advisory Board Intellectual Property Capella (Scientific Presentations) Our Products Product Listing Our News Newsroom Press Releases Capella (Scientific Presentations) Media Kit Investors For Investors Stock I
Alnylam Named a Science Magazine Top Employer for 2nd Year in a Row | Alnylam® Newsroom Skip to main content Investors For Investors Stock Information Investors Toolkit Events & Presentations Financial Information SEC Filings Corporate Governance Analyst Coverage Financial Statements Ownership Profile Annual Meetings Press Releases Capella (Scientific Presentations) FAQs Medical Professionals For Medical Professionals Genetic Testing & Counseling Early Access Program Medical Publication Support Investigator Initiated Studies (IIS) Patients For Patients Amyloidosis Acute Hepatic Porphyria Prima
6 in a Row! Alnylam Named a Boston Globe Top Place to Work for 2020 | Alnylam® Newsroom Skip to main content Investors For Investors Stock Information Investors Toolkit Events & Presentations Financial Information SEC Filings Corporate Governance Analyst Coverage Financial Statements Ownership Profile Annual Meetings Press Releases Capella (Scientific Presentations) FAQs Medical Professionals For Medical Professionals Genetic Testing & Counseling Early Access Program Medical Publication Support Investigator Initiated Studies (IIS) Patients For Patients Amyloidosis Acute Hepatic Porphyria Prima
Careers | Alnylam® Newsroom Skip to main content Investors For Investors Stock Information Investors Toolkit Events & Presentations Financial Information SEC Filings Corporate Governance Analyst Coverage Financial Statements Ownership Profile Annual Meetings Press Releases Capella (Scientific Presentations) FAQs Medical Professionals For Medical Professionals Genetic Testing & Counseling Early Access Program Medical Publication Support Investigator Initiated Studies (IIS) Patients For Patients Amyloidosis Acute Hepatic Porphyria Primary Hyperoxaluria Patient Services Genetic Testing and Counse
Alnylam Presents Phase I Data for ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers, at American Society of Clinical Oncology (ASCO) Meeting | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Two of favorites- Alnylam and OTS turned 20 this year. Coincidentally, it marks 20 years for my biotech adventure as well. It began in 2002 at Ribozyme Pharmaceuticals that reinvented itself as Sirna… | Vasant Jadhav | 57 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update
Alnylam Pharmaceuticals and Gen Sign Distribution Agreement in Turkey for ONPATTRO® (patisiran), the First-in | Alnylam Skip to main content Investors For Investors Stock Information Investors Toolkit Events & Presentations Financial Information SEC Filings Corporate Governance Analyst Coverage Financial Statements Ownership Profile Annual Meetings Press Releases Capella (Scientific Presentations) FAQs Medical Professionals For Medical Professionals Genetic Testing & Counseling Early Access Program Medical Publication Support Investigator Initiated Studies (IIS) Patients For Patients Amyloidos … apan for the treatment of hATTR amyloidosis with polyneuropathy. Based on Nobel Prize-winning science, ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin (TTR). It is designed to target and silence TTR messenger RNA, thereby blocking the production of TTR protein before it is made. ONPATTRO blocks the production of TTR in the liver, reducing its accumulation in the body’s tissues in order to halt or slow down the progression of the polyneuropat … breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA … ic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO ® (patisiran), approved in the U.
EX-99.1 2 a20251203exhibit991.htm EX-99.1 Document Exhibit 99.1 Contacts: Alnylam Pharmaceuticals, Inc. Christine Akinc (Investors and Media) 617-682-4340 Josh Brodsky (Investors) 617-551-8276 Alnylam Pharmaceuticals Announces Changes to Board of Directors – Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director – CAMBRIDGE, Mass., December 3, 2025 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of … hrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger … ople afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products include AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIV
Careers | Alnylam Skip to main content Beware of recruitment scams. Learn how to protect yourself and verify legitimate Alnylam opportunities and recruiting communication. Our Company About Alnylam Leadership Diversity, Equity & Inclusion Patient Access Philosophy Corporate Responsibility Alnylam Challengers Transparency Grants & Giving Investigator Initiated Studies (IIS) Our Science The Science of RNAi Delivery Platforms Making Our Medicines Therapeutic Areas Pipeline Clinical Trials Scientific Advisory Board Intellectual Property Capella (Scientific Presentations) Our Products Produ
Alnylam's Executive VP on Value-Based Agreements and Global Strategy | Thanos Tsagkadouras posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to j … will pay more for existing medications, with increased foreign revenue used to fund additional R&D and cut US prices. This principle “allows us to retrain other countries to appropriately value innovation for their citizens, to appropriately understand what fair share means to contribute global R&D.” ● Pfizer will “onshore 100% of the value of all imports.” MFN pricing will be based on prices after fees and rebates in Canada, Denmark, France, Germany, Italy, Japan, S
How Alnylam’s Manufacturing Investments Bring RNAi Therapeutics to More Patients, Faster | Alnylam® Newsroom Skip to main content Investors For Investors Stock Information Investors Toolkit Events & Presentations Financial Information SEC Filings Corporate Governance Analyst Coverage Financial Statements Ownership Profile Annual Meetings Press Releases Capella (Scientific Presentations) FAQs Medical Professionals For Medical Professionals Genetic Testing & Counseling Early Access Program Medical Publication Support Investigator Initiated Studies (IIS) Patients For Patients Amyloidosis Acute He … ent in manufacturing has been critical for Alnylam’s ability to translate Nobel Prize-winning science into real-world impact. It is the backbone that allows us to sustainably deliver RNAi therapeutics to more patients, and in a way that sets the gold standard for siRNA manufacturing. Learn more about how Alnylam makes its medicines here, or visit our Patient Access Philosophy page to see how we ensure patients who can benefit from our therapies are able to receive them. Want
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027 | Alnylam Skip to main content Investors For Investors Stock Information Investors Toolkit Events & Presentations Financial Information SEC Filings Corporate Governance Analyst Coverage Financial Statements Ownership Profile Annual Meetings Press Releases Capella (Scientific Presentations) FAQs Medical Professionals For Medical Professionals Genetic Testing & Counseling Early Access Program Medical Publication Support Investigator Initiated Studies (IIS) Patients For Patients Amyloidosis Acute Hepatic Porphyria Pri … ople afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products include AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosira
Alnylam charts five-year plan as sales of key drug miss expectations | STAT Skip to Main Content Manage alerts for this article Email this article Share this article Obesity Donald Trump weight loss Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest Series … scribe to STAT+. Subscribe Log In biotechnology , JPM , Pharmaceuticals , STAT+ Submit a correction request Reprints Matthew Herper Senior Writer, Medicine, Editorial Director of Events Matthew Herper covers medical innovation — both its promise and its perils. Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our Privacy Policy and Terms of Servi … iotech Biotech June 24, 2026 STAT Plus: Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval By Jason Mast Advertisement Biotech Biotech June 24, 2026 STAT Plus: Ophthalmology venture grabs investors’ attention, raises $330 million By Allison DeAngelis The Readout The Readout June 23, 2026 STAT Plus: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program By Elaine Chen Exclusive Exclusive June 23,
Alnylam Pharmaceuticals - 2025 AAN Annual Meeting Skip to Main Content Alnylam Pharmaceuticals Event starts in: 00 DAYS 00 HRS 00 MINS 00 SECS April 5 to April 9, 2025 San Diego, CA HOMEPAGE EXHIBITOR RESOURCE CENTER EXHIBITOR LISTING Login Create Account Alnylam Pharmaceuticals Booth #1941 About About Contact About Contact Name Alnylam Pharmaceuticals Company Description About Alnylam Pharmaceuticals Since its founding, Alnylam has led the translation of RNA interference (RNAi) into a new class of approved and investigational medicines for rare genetic, cardio-metabolic, hepatic infectious, a
Inceptive Skip to Main Content Models Models Partnerships Partnerships Team Team Careers Careers Media Media Back Home Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics June 3, 2026 − Collaboration is valued at up to $2B with upfront consideration of $30M − Alliance pairs Alnylam’s RNAi platform and 20+ years of proprietary data with Inceptive’s foundation models and AI expertise to catalyze progress beyond rational drug design − Partnership designed to accelerate timelines and unlock innovative oligonucleotide designs CAMBRIDGE, Mass. a … , or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale imp
Alnylam Pharmaceuticals - BIO Patient Advocacy Changemakers Event 2025 Skip To Main Content About Us Show submenu for: About Us Learn about BIO Contact Us 2025 Participating Organizations 2025 Program Show submenu for: 2025 Program 2025 Sessions 2025 Speakers Sponsorship Show submenu for: Sponsorship Become a Sponsor 2025 Sponsors More Show more menu items About Us Show submenu for: About Us Learn about BIO Contact Us 2025 Participating Organizations 2025 Program Show submenu for: 2025 Program 2025 Sessions 2025 Speakers Sponsorship Show submenu for: Sponsorship Become a Sponsor 2025 Sponsors
Novartis to acquire Regulus in deal for kidney disease drug | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore … ks from which it struggled to recover. It also had difficulty finding the right application for its drugmaking technology, trying its hand at a hepatitis C treatment that didn’t pan out. Since 2021, Regulus shares have traded below $4 per share. The drug at the heart of its deal with Novartis, called farabursen, entered the clinic in 2022. Farabursen targets miR-17, which researchers have identified as potentially relevant to kidney disease. People with ADPKD have few treatme
John Maraganore, pioneering RNAi executive, to step down as Alnylam CEO | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Scien … e longtime CEO of Alnylam Pharmaceuticals and a pioneering executive in a Nobel Prize-winning field of drugmaking known as RNA interference, will leave the company as part of a planned transition. Alnylam announced Thursday that current company president and chief operating officer Yvonne Greenstreet will take over for Maraganore as the company's full-time CEO by the end of the year. Maraganore, who has led Alnylam for nearly two decades, will help in a consulting role throug … , based on discoveries scientists Andrew Fire and Craig Mello would win a Nobel Prize for in 2006, represented a completely new way of making drugs. "That was an opportunity I just could not walk away from," Maraganore said in 2014 . "How could you say no?" Alnylam invested heavily in the effort, snapping up a series of patents as it went on to become the RNAi field's biggest company. Still, Alnylam spent 16 years trying to turn that research into a business. Pharmaceutical c
Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement - GHIAA Skip to content MAPGuide Provision Database Search By Issue By Agreement Features Advanced Search Agreement Index Key Issues Methodology Database Tutorials Resources Equitable Access Toolkit Equitable Access Policies Equitable Access Glossary Commentaries Consulting Services MAPGuide Provision Database Search By Issue By Agreement Features Advanced Search Agreement Index Key Issues Methodology Database Tutorials Resources Equitable Access Toolkit Equitable Access Policies Equitable … ccurate scientific records that any other party can access or obtain copies of. Submit quarterly reports that summarizes the status of the research program, new foreground technology and publications, and research program funds expended. Promptly and fully disclose any patentable foreground IP in a formal notice separate from any other required report. Notify UBC and AlCana when it enters into sublicensing agreements. Alnylam must: Notify UBC and AlCana when it enters into su … consideration. 5.2 Required Reports. During the Research Term, each Party will submit to the JSC at the end of each Contract Quarter a written report summarizing (a) the status of the Research Program, (b) any Program Developments and publications/abstracts made during such Contract Quarter, and (c) Research Program funds expended during that period. 7. Program Developments and Program Materials 7.1 Disclosure of Patentable Program Developments . The Parties will promptly an … provisions, which may be attributed or anonymized. Please use the form below to submit an agreement or provision. Submit Agreement or Provision The MAPGuide Ⓡ by the Global Healthcare Innovation Alliance Accelerator is licensed under CC-BY-NC-ND 4.0 . To request permission for commercial or derivative use, contact [email protected] . This website and the MAPGuide Ⓡ are provided for general informational purposes only. By using this website and any element of the MAPGuide Ⓡ , yo … de Ⓡ platform and Equitable Access Toolkit was supported by the Wellcome Trust (grant numbers 219632/Z/19/Z, 221648/Z/20/Z, 225262/Z/22/Z, and 325085/Z/25/Z). If you are interested in providing funding or an in-kind contribution to support GHIAA’s continuing equitable access advocacy work and resource development activities, please contact us usi
Alnylam Pharmaceuticals – University of British Columbia- AlCana Technology, Sponsored Research Agreement - GHIAA Skip to content MAPGuide Provision Database Search By Issue By Agreement Features Advanced Search Agreement Index Key Issues Methodology Database Tutorials Resources Equitable Access Toolkit Equitable Access Policies Equitable Access Glossary Commentaries Consulting Services MAPGuide Provision Database Search By Issue By Agreement Features Advanced Search Agreement Index Key Issues Methodology Database Tutorials Resources Equitable Access Toolkit Equitable Access Policies Equitable … r a publication delayed for a specified period to permit the filing of a patent application. Annotations This Sponsored Research Agreement is between Alnylam Pharmaceuticals, Inc. (“ Alnylam ”), a publicly traded biopharmaceutical firm located in Massachusetts, the University of British Columbia (“ UBC ”) and AlCana Technologies, Inc. (“ AlCana ”), a private biotechnology company located in Vancouver (now known as Acuitas Therapeutics). The Agreement governs a joint research … e time Alnylam notifies such Party that it wants to file or have filed a patent application on the Program Development. Download Full Agreement We are seeking additional content for the MAPGuide Ⓡ in the form of either full agreements or individual provisions, which may be attributed or anonymized. Please use the form below to submit an agreement or provision. Submit Agreement or Provision The MAPGuide Ⓡ by the Global Healthcare Innovation Alliance Accelerator is licensed und … de Ⓡ platform and Equitable Access Toolkit was supported by the Wellcome Trust (grant numbers 219632/Z/19/Z, 221648/Z/20/Z, 225262/Z/22/Z, and 325085/Z/25/Z). If you are interested in providing funding or an in-kind contribution to support GHIAA’s continuing equitable access advocacy work and resource development activities, please contact us using the form below. Global Healthcare Innovation Alliance Accelerator is a 501(c)(3) non-profit recognized by the IRS. Contact Us Sen … om GHIAA and have read and agree to the Privacy Policy and Terms of Service . . Submit Agreement Type Any Agreement Types Contract Manufacturing License Other R&D Collaboration R&D Funding Supply/Purchase Technology Transfer Select Partner Type Any Partner types Academic institution Funder Government Industry Multilateral organization Non
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Thank you to... - Huntington's Disease Society of America Facebook Log In Huntington's Disease Society of America's Post Huntington's Disease Society of America Verified account April 29, 2025 · Shared with Public Thank you to Alnylam Pharmaceuticals for being a Bronze Sponsor at the 40th Annual #HDSAConvention ! To learn more about Sponsorship, Exhibitor and Registration information, please visit: https://hdsa.org/about-hdsa/annual-convention/ #LetsTalkAboutHD #HuntingtonsDisease #HDSAFamily #FamilyIsEverything #HDSAConvention #40thHDSAConvention All reactions: 20 2 shares
Information for Medical Professionals | Alnylam Skip to main content Our Company About Alnylam Leadership Diversity, Equity & Inclusion Patient Access Philosophy Corporate Responsibility Alnylam Challengers Transparency Grants & Giving Investigator Initiated Studies (IIS) Our Science The Science of RNAi Delivery Platforms Making Our Medicines Therapeutic Areas Pipeline Clinical Trials Scientific Advisory Board Intellectual Property Capella (Scientific Presentations) Our Products Product Listing Our News Newsroom Press Releases Capella (Scientific Presentations) Media Kit Investors For … Alnylam may be able to provide support for these requests. Learn More › Alnylam Grant Information Alnylam is committed to supporting the medical and scientific understanding of our therapeutic areas of interest for healthcare professionals. Additionally, we are committed to supporting educational programs and initiatives spearheaded by organizations focused on patient advocacy, community education and support, and other scientific efforts related to our therapeutic areas of i … rapeutic areas of interest. To learn more about grants, sponsorships, or how to submit a grant request, visit our grants page . Access to Investigational Medicines Alnylam is dedicated to developing new therapies that have a positive impact on patient health, and to serving patients, patient families, and patient communities through education, empathy, and awareness. We understand that there are seriously ill patients who will not be eligible for our clinical trials and may n
Alnylam Request Management System Home Register Sign In GRANTS AND GIVING The Alnylam Grants and Giving Office is committed to supporting innovative, high-quality initiatives that provide healthcare professionals and patients with evidence-based, clinically-relevant, and performance-based education and improve patient health. Activities and programs should strive to ultimately improve patient care and must be compliant with all applicable legal and regulatory requirements. Below is information on the process and funding types that will be considered for fundi … ttee on a monthly basis All other types of funding are formally considered on a rolling basis Requesting organization will receive an email notification of approval or denial directly from the funding portal All approved requests are subject to the electronic execution of a letter of agreement A reconciliation of grants must be complete within 90 days of the activity or program end date Any unused funds must be returned to Alnylam Failure to complete a reconciliation and/or r … nal uses to provide services for patients, the public, or the profession. A CME grant is an unsolicited funding request that may be accredited or non-accredited. Alnylam may not receive any tangible business benefit. Transparency of Alnylam’s support is required and is not considered a tangible benefit. Educational Grants (non-CME) Funding provided in response to an unsolicited request from an eligible third-party organization that has independently applied for grant su … ure, expert faculty, curriculum, and ability to design and conduct a successful fellowship program. Responses to Requests for Proposals Throughout the year, Alnylam will post Request for Proposals (RFP) to inform organizations and qualified medical education providers that we are interested in receiving requests for independent medical education activities pertinent to Alnylam’s areas of interest and aligned to specifications outlined in our RFPs. The grantee is respons … is responsible for the design and execution of the initiative supported by the grant, including compliance with any regulatory requirements. Alnylam may not receive any tangible business benefit. Transparency of Alnylam’s support is required and is not considered a tangible benefit. Sponsorships Alnylam considers support for
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics | Alnylam Skip to main content Investors For Investors Stock Information Investors Toolkit Events & Presentations Financial Information SEC Filings Corporate Governance Analyst Coverage Financial Statements Ownership Profile Annual Meetings Press Releases Capella (Scientific Presentations) FAQs Medical Professionals For Medical Professionals Genetic Testing & Counseling Early Access Program Medical Publication Support Investigator Initiated Studies (IIS) Patients For Patients Amyloidosis Acut … , or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale imp
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growi | Alnylam Skip to main content Investors For Investors Stock Information Investors Toolkit Events & Presentations Financial Information SEC Filings Corporate Governance Analyst Coverage Financial Statements Ownership Profile Annual Meetings Press Releases Capella (Scientific Presentations) FAQs Medical Professionals For Medical Professionals Genetic Testing & Counseling Early Access Program Medical Publication Support Investigator Initiated Studies (IIS) Patients For Patients Amyloido … breakthrough that happens once every decade or so,” and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam’s RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) … ople afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products include AMVUTTRA® (vutrisiran), ONPATTRO® (patisiran), GIVLAARI® (givosira
Exhibitor - Alnylam Pharmaceuticals | UW–Madison ICEP Jump to content UW–Madison ICEP Search Open menu Cart Log in Create account Bookmark/Search this post Facebook X LinkedIn Forward Home Catalog Grand Rounds & other RSS Live Grand Rounds, Journal Club, Case Conference Online/Enduring Grand Rounds MOC Learning Communities Clinical Teaching Learning Community Mental Health Pediatric Obesity FAQ & Updates Update Email Preferences Frequently Asked Questions Planning CE About ICEP Contact Us You are here Home Exhibitor - Alnylam Pharmaceuticals www.hattramyloidosis.com About Alnylam Pharm … ic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics are a clinically validated approach for the treatment of rare diseases with unmet medical need and prevalent diseases. Alnylam is headquartered in Cambridge, MA. For more information, please visit www.alnylam.com . Resources are intended for US Healthcare Professionals only. For additional information about hATTR amyloidosis, please see the resources availa
We’re proud to continue our sponsorship and involvement at this year's Asembia Summit, where key stakeholders will come together to discuss the future of rare disease care. Join our session on… | Alnylam Pharmaceuticals LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your ch